Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.

Mohammed I, Iliyasu G, Habib AG.

Pathog Glob Health. 2017 Feb;111(1):1-6. doi: 10.1080/20477724.2016.1274068. Epub 2017 Jan 12. Review.

PMID:
28081671
2.

Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

Basta NE, Borrow R, Berthe A, Dembélé AT, Onwuchekwa U, Townsend K, Boukary RM, Mabey L, Findlow H, Bai X, Sow SO.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S547-53. doi: 10.1093/cid/civ602.

3.

Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac.

Tang Y, Plikaytis BD, Preziosi MP, Borrow R.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S531-9. doi: 10.1093/cid/civ601.

4.

Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.

Diallo A, Sow SO, Idoko OT, Hirve S, Findlow H, Preziosi MP, Elie C, Kulkarni PS, Parulekar V, Diarra B, Cheick Haidara F, Diallo F, Tapia M, Akinsola AK, Adegbola RA, Bavdekar A, Juvekar S, Chaumont J, Martellet L, Marchetti E, LaForce MF, Plikaytis BD, Enwere GC, Tang Y, Borrow R, Carlone G, Viviani S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S521-30. doi: 10.1093/cid/civ518.

5.

Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of Age.

Tapia MD, Findlow H, Idoko OT, Preziosi MP, Kulkarni PS, Enwere GC, Elie C, Parulekar V, Sow SO, Haidara FC, Diallo F, Doumbia M, Akinsola AK, Adegbola RA, Kampmann B, Chaumont J, Martellet L, Marchetti E, Viviani S, Tang Y, Plikaytis BD, LaForce FM, Carlone G, Borrow R.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S514-20. doi: 10.1093/cid/civ672.

6.

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.

Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S483-8. doi: 10.1093/cid/civ500. Review.

7.

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.

Djingarey MH, Diomandé FV, Barry R, Kandolo D, Shirehwa F, Lingani C, Novak RT, Tevi-Benissan C, Perea W, Preziosi MP, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S434-41. doi: 10.1093/cid/civ551. Review.

8.

Technical Development of a New Meningococcal Conjugate Vaccine.

Frasch CE, Kapre SV, Lee CH, Préaud JM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S404-9. doi: 10.1093/cid/civ595. Review.

9.

How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Gasparini R, Panatto D, Bragazzi NL, Lai PL, Bechini A, Levi M, Durando P, Amicizia D.

J Immunol Res. 2015;2015:189153. doi: 10.1155/2015/189153. Epub 2015 Aug 17. Review.

10.

Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.

Kristiansen PA, Ba AK, Ouédraogo AS, Sanou I, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Saga IM, Misegades L, Clark TA, Préziosi MP, Caugant DA.

BMC Infect Dis. 2014 Dec 4;14:663. doi: 10.1186/s12879-014-0663-4.

11.

Emerging, evolving, and established infectious diseases and interventions.

Halloran ME, Longini IM Jr.

Science. 2014 Sep 12;345(6202):1292-4. doi: 10.1126/science.1254166.

13.

HHS--supporting global immunization through policies, programs, and partnerships.

Daulaire N.

Public Health Rep. 2014;129 Suppl 3:1-3. No abstract available.

14.

Soil dust aerosols and wind as predictors of seasonal meningitis incidence in Niger.

Pérez García-Pando C, Stanton MC, Diggle PJ, Trzaska S, Miller RL, Perlwitz JP, Baldasano JM, Cuevas E, Ceccato P, Yaka P, Thomson MC.

Environ Health Perspect. 2014 Jul;122(7):679-86. doi: 10.1289/ehp.1306640. Epub 2014 Mar 17.

15.

Benefits of using vaccines out of the cold chain: delivering meningitis A vaccine in a controlled temperature chain during the mass immunization campaign in Benin.

Zipursky S, Djingarey MH, Lodjo JC, Olodo L, Tiendrebeogo S, Ronveaux O.

Vaccine. 2014 Mar 14;32(13):1431-5. doi: 10.1016/j.vaccine.2014.01.038. Epub 2014 Feb 19.

16.

Review of meningococcal vaccines with updates on immunization in adults.

Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo GS.

Hum Vaccin Immunother. 2014;10(4):995-1007. Epub 2014 Feb 5. Review.

17.

Methods for identifying Neisseria meningitidis carriers: a multi-center study in the African meningitis belt.

Basta NE, Stuart JM, Nascimento MC, Manigart O, Trotter C, Hassan-King M, Chandramohan D, Sow SO, Berthe A, Bedru A, Tekletsion YK, Collard JM, Jusot JF, Diallo A, Basséne H, Daugla DM, Gamougam K, Hodgson A, Forgor AA, Omotara BA, Gadzama GB, Watkins ER, Rebbetts LS, Diallo K, Weiss NS, Halloran ME, Maiden MC, Greenwood B.

PLoS One. 2013 Oct 23;8(10):e78336. doi: 10.1371/journal.pone.0078336. eCollection 2013.

18.

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.

Pajon R, Fergus AM, Granoff DM.

PLoS One. 2013 Jun 21;8(6):e66536. doi: 10.1371/journal.pone.0066536. Print 2013.

19.

The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?

Maiden MC.

Philos Trans R Soc Lond B Biol Sci. 2013 Jun 24;368(1623):20120147. doi: 10.1098/rstb.2012.0147. Print 2013 Aug 5. Review.

20.

Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt.

Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML.

PLoS One. 2013 May 9;8(5):e63605. doi: 10.1371/journal.pone.0063605. Print 2013.

Supplemental Content

Support Center